overall survival

BOSTON, Aug. 4, 2026 CervoMed Inc. announced that its investigational oral therapy neflamapimod has been granted an Innovation Passport...

OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...

TOKYO, July 31, 2026 Daiichi Sankyo and AstraZeneca announced that the European Commission (EC) has approved Datroway® (datopotamab deruxtecan)...

CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...

COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...

SYDNEY, Australia, July 13, 2026 Immutep announced positive mature overall survival data from its investigator-initiated Phase 1 INSIGHT-003 trial...

SHANGHAI, China, July 10, 2026 Hansoh Pharmaceutical Group Co., Ltd. has announced that its Phase III ARTEMIS-008 clinical trial...

Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...

Basel, Switzerland, July 2, 2026 Roche has announced positive top-line results from its pivotal Phase III Krascendo 1 clinical...

PRINCETON, N.J., June 30, 2026 Kyowa Kirin has announced new clinical analyses demonstrating that mogamulizumab continues to deliver meaningful...